Skip to content
Gigantum.net
Science & space

The FDA’s peptide circus is underway.

An advisory panel, stacked with RFK Jr.’s pro-peptide appointees, has voted to add BPC-157 and KPV to the bulk compounding list. This is despite FDA staff clinicians stating that there’s no convincing evidence. Central to the argument is whether allowing compounding will curtail the gray market or expose the public to unnecessary risk. Internally screaming. [Media: https://www.youtube.com/live/DhDC0DAYdBI]

· 69 words

An advisory panel, stacked with RFK Jr.’s pro-peptide appointees, has voted to add BPC-157 and KPV to the bulk compounding list. This is despite FDA staff clinicians stating that there’s no convincing evidence. Central to the argument is whether allowing compounding will curtail the gray market or expose the public to unnecessary risk. Internally screaming.

Sign in to see your notifications or create an account to join the conversation.

Topics in this story

Gathered from external sources. Rights to this text belong to whoever originally published it.

Tuesday, November 17, 2026

© 2026 Gigantum.net. Content gathered automatically from external sources; rights to each text belong to whoever originally published it.